about
Brainstem control of locomotion and muscle tone with special reference to the role of the mesopontine tegmentum and medullary reticulospinal systemsParkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and DiagnosisPharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration.Linear and Curvilinear Trajectories of Cortical Loss with Advancing Age and Disease Duration in Parkinson's Disease.Cortical Implications of Advancing Age and Disease Duration in Parkinson's Disease Patients with Postural Instability and Gait Dysfunction.Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease.Neuroimaging as a window into gait disturbances and freezing of gait in patients with Parkinson's disease.A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.Copy number variability in Parkinson's disease: assembling the puzzle through a systems biology approachThe neurobiological basis of cognitive impairment in Parkinson's disease.Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson's disease: evidence for dopaminergic basis?The Serotonin Receptor 6 Antagonist Idalopirdine and Acetylcholinesterase Inhibitor Donepezil Have Synergistic Effects on Brain Activity-A Functional MRI Study in the Awake RatThe relationships between mild cognitive impairment and phenotype in Parkinson's diseaseDeficits in cholinergic neurotransmission and their clinical correlates in Parkinson's disease.Subchronic treatment of donepezil rescues impaired social, hyperactive, and stereotypic behavior in valproic acid-induced animal model of autism.Bioactive compounds from macroalgae in the new millennium: implications for neurodegenerative diseases.Regulation of the protocadherin Celsr3 gene and its role in globus pallidus development and connectivity.Is synaptic loss a unique hallmark of Alzheimer's disease?Slowing of EEG background activity in Parkinson's and Alzheimer's disease with early cognitive dysfunctionAn animal model mimicking pedunculopontine nucleus cholinergic degeneration in Parkinson's disease.Modeling falls in Parkinson's disease: Slow gait, freezing episodes and falls in rats with extensive striatal dopamine lossIn vitro and ex vivo characterization of (-)-TZ659 as a ligand for imaging the vesicular acetylcholine transporterOlfactory dysfunction and neurotransmitter disturbance in olfactory bulb of transgenic mice expressing human A53T mutant α-synuclein.Glial response in the rat models of functionally distinct cholinergic neuronal denervations.Modeling Parkinson's disease falls associated with brainstem cholinergic systems decline.Synthesis and biological characterization of a promising F-18 PET tracer for vesicular acetylcholine transporter.Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease.Associations between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease.Motor Subtype as a Predictor of Future Working Memory Performance in Idiopathic Parkinson's Disease.Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease.Cholinergic dysfunction contributes to gait disturbance in early Parkinson's diseaseVirtual reality for rehabilitation in Parkinson's disease.Abnormal metabolic pattern associated with cognitive impairment in Parkinson's disease: a validation study.Differential expression of galanin in the cholinergic basal forebrain of patients with Lewy body disorders.The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's DiseaseMemory Similarities Between Essential Tremor and Parkinson's Disease: A Final Common Pathway?Deep brain stimulation of the subthalamic nucleus, but not dopaminergic medication, improves proactive inhibitory control of movement initiation in Parkinson's diseaseLevodopa Is a Double-Edged Sword for Balance and Gait in People With Parkinson's Disease.Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease.Glutathione metabolism and Parkinson's disease.
P2860
Q26779826-B10277CC-5A4C-4392-85CB-526FBC5F41DEQ28384572-9AC5CB73-EF93-4347-9487-32DADE4C8626Q30244035-1AA0442E-10E3-4D71-A9C7-847FB47382CBQ30276531-F5A984A6-6123-4D60-A8F1-DE480B3C7EAEQ30276836-2395BADE-DC3E-44F8-9B26-904D77415C8BQ30525353-88BC161E-08F5-491C-A05B-4FA005E25D5EQ30679603-2F30E54A-46BC-452C-B645-029D25ABCB06Q33165693-DCA4D068-3ACF-498F-813D-805F9AA019D4Q33364337-303B5375-E8DC-4F91-BD6B-B6827C6DCA9AQ33724698-A84DD6B8-7C36-4C64-B436-25A9DAC76968Q33731267-23177FB2-695F-44D5-A3D8-0FFFEEA5CC19Q33785842-BBCD650D-82F8-4724-9115-7AB57B80C7A6Q33917203-96AAE530-50FE-4A70-854B-63207F39EFB1Q33917311-7A723A33-2C82-487A-A4C7-074EF90B1301Q34061622-140D62F1-5C4B-4458-BF8C-5387764D6AC7Q34260323-62162FBF-0D08-4E70-991F-ECBA937FC06AQ34297959-C1439ADE-72EA-4926-B178-146189374FADQ34504659-953A6E52-9DD7-47AA-B2B0-BD5A79ABD6DDQ34531520-BE8D59D8-80F8-4480-834C-2BE8BB715458Q35057159-AD72C5AC-B92E-4578-A059-B098C4965330Q35070996-F0932DC1-E99E-4C95-91D0-029A3B0F2618Q35204649-B658AD62-C78E-45FD-BDC4-DD16EE2473B0Q35208334-1AB79C38-63BD-407E-9F9A-87275F3A2F5CQ35273342-CB6D4877-335E-4408-9673-6F5C6B4EAB70Q35360176-0459A1FE-C1FE-472D-A528-B29A1185E65BQ35915048-37B53BFE-0CCC-4AD2-A089-54961203F076Q35915052-085FDF68-10E5-43C1-AC68-CFBA0433DFD6Q35944999-C941CF53-40F4-4BDF-BE4E-D55C64377753Q35970595-AF19D268-A0AF-409A-B4AC-2A3D2DDDD008Q36154790-956266B8-1CFE-43BC-B700-985CEEF067BAQ36218725-3B450E55-6CE2-426F-91E7-BDB2FA7C2278Q36230160-415C855D-B86D-46EA-ACB9-86EE58A5A4C8Q36267429-8BEFC955-64E9-4517-B514-F193D7E99773Q36337159-E8B5ABEB-0920-44F7-B58C-A86F934C8C1FQ36494212-FDB9E03E-BAD9-476D-8B2F-091AA0A35C70Q36535822-643AEB7B-FB56-42BE-9AE6-BA5C94833D4BQ36568655-9B2CEC1F-8A2A-4C6D-A550-F777A0CB984DQ36585373-C7EF83C4-EFF5-41BF-9B47-A037C2B0CB35Q37056546-790CD919-A819-460B-B3B1-32AF2486E405Q37078480-A9C31F63-952C-489D-9135-6CE11E47A3AD
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The cholinergic system and Parkinson disease.
@en
The cholinergic system and Parkinson disease.
@nl
type
label
The cholinergic system and Parkinson disease.
@en
The cholinergic system and Parkinson disease.
@nl
prefLabel
The cholinergic system and Parkinson disease.
@en
The cholinergic system and Parkinson disease.
@nl
P2860
P1476
The cholinergic system and Parkinson disease.
@en
P2093
Roger L Albin
P2860
P304
P356
10.1016/J.BBR.2009.12.048
P407
P577
2010-01-07T00:00:00Z